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14.96 ± 0.95; Factor 2, 6.10 ± 0.71; Factor 3, 6.24 ± 0.77; Factor
4, 10.58 ± 0.73; Factor 5, 2.61 ± 0.41; Factor 6, 33.96 ± 2.33;
and Factor 7, 2.35 ± 0.30. Physical Functioning proved the
largest and most inﬂuential factor in measuring QOL. Cron-
bach’s alpha was 0.9765, indicating correct allocation of indi-
vidual items to a particular factor. The tool’s robustness was
shown by the test-retest scores, which lacked signiﬁcant differ-
ences between two completions of the questionnaire. CON-
CLUSIONS: QOL-NET should be invaluable for clinical trials.
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OBJECTIVES: The aim of this study was to develop health state
descriptions for patients with metastatic colorectal cancer
(mCRC)—either stable on treatment, disease progression or
“end of life”. Health states also contrasted intravenous and oral
therapy. These health states can be used subsequently to derive
utility values for use in cost utility analyses. METHODS: An
interview discussion guide was produced based on literature
review and clinical input. This focused on the symptoms of
mCRC, the impact on different areas of functioning (physical,
social, emotional, sexual, and cognitive), and health related
quality of life. Draft health states were developed based on analy-
ses of in-depth exploratory interviews with oncologists (n = 1)
and specialist oncology nurses (n = 3). These health states were
then edited and improved through two further rounds of inter-
views (nurses n = 5; oncologists n = 7; psychometricians n = 2).
The ﬁnal health states were piloted with ﬁve members of the
general public for ease of comprehension and obvious errors of
interpretation. This piloting involved taking the participant
through the full standard gamble interview and then undertak-
ing a full cognitive debrief interview exploring participants’
interpretation of the health states. RESULTS: The analysis of the
literature suggested seven main areas to focus on which included
physical, social, sexual, and cognitive functioning, emotional
wellbeing, side effects and symptoms. The third round of inter-
views with clinical staff indicated that the health states were a
fair reﬂection of the disease. The piloting work also indicated
that members of the general public were able to easily under-
stand the concepts in the health states. No major changes were
required following the pilot work. CONCLUSIONS: Health
states describing the impact of stages of mCRC have been devel-
oped. These health states are designed to be used in societal or
patient based valuation studies. An example ﬁnal health state
will be presented.
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OBJECTIVES: The goal of this study was to estimate an algo-
rithm to convert responses to the Functional Assessment of
Cancer Therapy—General (FACT-G) to current health time
trade-off (TTO) utilities. METHODS: Data for 1433 cancer
patients were randomly separated in to construction and valida-
tion samples. FACT-G questions were selected for inclusion
based upon correlation with ECOG-PS scores and TTO utilities,
and mean scores, and item response theory was used to collapse
response categories. Ordinary least squares regression with the
constant constrained to one was used to estimate the algorithm.
RESULTS: Four FACT-G questions: lack of energy, feel sick, able
to work, and able to enjoy life were selected for the algorithm,
using between two and four response categories each. The algo-
rithm estimated mean utility for the full validation sample within
three points of observed mean utility (0.805 versus 0.832, p <
0.01). Mean utilities are well predicted (difference less than three
percentage points, and not statistically signiﬁcant) for most sub-
groups deﬁned by ECOG-PS and SF-36 physical functioning
scores, and responses to the FACT-G overall quality of life item.
However, the algorithm systematically over-predicted utility for
poor health by each measure. CONCLUSIONS: This algorithm
estimates mean cancer patient preferences for FACT-G based
health states with group level accuracy comparable to other pref-
erence-based measures, and may be applied to both retrospec-
tively and prospectively collected clinical trials data. This
patient-based preference algorithm expands the tools available
for use in cost-utility analyses and treatment comparisons and is
useful in multiple situations, including when the patient is the
primary payer of care, and when understanding how patients
view treatment is desired.
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OBJECTIVES: Propensity score matching fails especially when
there is lack of overlap in the covariate distributions. In this
paper, we analyzed three different methods to adjust propensity
score matching under lack of overlap. METHODS: Most com-
monly used method is to drop all control units with an estimated
propensity score lower than the smallest value, or larger than the
largest value, for the estimated propensity score among the
treated units. The second method is discarding units with covari-
ate values at which the estimated density is below some thresh-
old and newly proposed third method is to estimate average
treatment effect on the optimal subpopulation. RESULTS: The
Market Scan private insurance data base was used in this study
which based upon prostate cancer patients. There was signiﬁ-
cance lack of overlap in data set. Pre-match data set contains
8576 prostate cancer patients and 30,550 control patients. If
one-to-one matching is applied, only 581 patients would match.
Most commonly method described in the methodology section
dropped 1137 patients from control sample. Kernel technique
matched 1250 treatment patients with 2126 control patients. By
using optimal subpopulation, optimal cut-off point is calculated
as 0.02 and it matched 1752 patients from treatment group with
2912 patients in control group. Health care expenditures for
prostate patients using three different methods were signiﬁcantly
different from the ones calculated using one-to-one matching
technique. CONCLUSION: Lack of overlap is the signiﬁcant
drawback of propensity score matching. We can improve
propensity score matching estimands by adjusting overlap dif-
ferences. Optimal subpopulation technique seems better since it
does not rely on arbitrary choices regarding thresholds for dis-
carding observations.
